09.08.2012 • News

Eli Lilly Raises 2012 Net Profit Forecast

Eli Lilly on Thursday raised its net profit forecast for 2012 to reflect income from the early payment of financial obligations from former partner Amylin Pharmaceuticals, which has been acquired by Bristol-Myers Squibb.

It said it now expects net earnings per share to range between $3.72 and $3.82. Its forecast for earnings excluding one-time items remains unchanged.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.